The Hindu Business Line : Dabur Pharma, Hospira likely to part ways

Advertisement

New Delhi Feb. 7 US-based pharma company Hospira might just have to say goodbye to its Indian partner, Dabur Pharma, now that the former has completed formalities to acquire the Australian Mayne Pharma, to claim world leadership in the speciality generic injectable pharmaceuticals business.

"Changes in shape and form of our arrangement with Hospira are inevitable in the current context," said Mr Ajay Vij, COO, Dabur Pharma. The company believes the new strategic alliances would clash with its own interests as Mayne is committed to its own Indian partners, including Zydus Cadila.

Having bagged US Food and Drug Administration approvals for its Carboplatin and Paclitaxel injectables, Dabur Pharma has big plans for the UK and the US for 2007. It recently sold its non-oncology business to support its ambitions.

The company has just set up a Florida office and appointed a former Teva official to head its operations in the US. "With the FDA approvals, the market now knows about us and we can go directly to our consumers," says Mr Vij. He added that the three-year-old relationship between Dabur Pharma and Hospira had been very good, and that future partnerships were being considered. Until now, Dabur was serving the US market through Dabur Oncology, its UK subsidiary and its marketing partner Hospira.

Dabur had entered into an agreement with Abbott Laboratories, one of the largest marketers of injectable pharmaceutical products in the US, in 2003 to make and sell prescription generic oncology products, before Hospira was carved out of Abbott's core global hospital products business.

Mayne also has a joint venture with Ahmedabad-based Zydus Cadila, signed in 2005, for a manufacturing facility in Gujarat.

More Stories on : Pharmaceuticals | Mergers & Acquisitions

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Rainy weekend forecast for North, northwest

Reliance MF to unveil new equity fund

Bell in talks with HAL, others to make commercial copters in India

1,000-acre SEZ for aerospace industry in Karnataka

Economy set to grow at 9.2%

PSU disinvestment back on Govt agenda

Green drive

Dabur Pharma, Hospira likely to part ways

Go to Tier II cities for expansion, Maran tells IT cos

Atos plans to triple India headcount to 5,000

Wipro hopes to close one buy this quarter

NSE revises F&O contract size

`We've to procure defence equipment worth $8-10 b'

FDI in retail: Panel to study impact on rural economy